Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin 5 monoclonal antibody, in healthy Japanese male subjects

Clinical Pharmacology in Drug Development

Volumn 5, Issue 2, 2016, Pages 102-108

  Tsukamoto, Naohiro ^a   Takahashi, Naoki ^a   Itoh, Hiroshi ^a   Pouliquen, Isabelle ^b  

^a Development and Medical Affairs Division   (Japan)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Anti interleukin 5; Blood eosinophils; Mepolizumab; Pharmacodynamics; Pharmacokinetics

Indexed keywords

INTERLEUKIN 5; MEPOLIZUMAB; PLACEBO; ANTIASTHMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHIL COUNT; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; JAPANESE (PEOPLE); MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG EFFECTS; EOSINOPHIL; HALF LIFE TIME; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; TIME FACTOR; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADULT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; EOSINOPHILS; HALF-LIFE; HUMANS; INTERLEUKIN-5; MALE; SINGLE-BLIND METHOD; TIME FACTORS; YOUNG ADULT;

EID: 84960111801     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.205     Document Type: Article

References (11)

1. Greenfeder S, Umland SP, Cuss FM, Chapman RW, Egan RW. Th2 cytokines and asthma-the role of interleukin-5 in allergic eosinophilic disease. Respir Res. 2001; 2(2):71-79.
2. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380(9842):651-659.
3. Smith DA, Minthorn EA, Beerahee M. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet. 2011; 50(4):215---227.
4. Wardlaw AJ, Brightling C, Green R, Woltmann G, Pavord I . Eosinophils in asthma and other allergic diseases. Br Med Bull. 2000; 56(4):985-1003.
5. Hamid Q, Azzawi M, Ying S, et al. Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest. 1991; 87(5):1541-1546.
6. Clutterbuck EJ, Hirst EM, Sanderson CJ. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood. 1989; 73(6):1504-1512.
7. Humbert M, Corrigan CJ, Kimmitt P, Till SJ, Kay AB, Durham SR. Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. Am J Respir Crit Care Med. 1997; 156(3 Pt 1):704-708.
8. Wang JM, Rambaldi A, Biondi A, Chen ZG, Sanderson CJ, Mantovani A. Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol. 1989; 19(4):701-705.
9. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008; 84(5):548-558.
10. Tabrizi MA, Tseng CML, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006; 11(1-2):81-88.
11. Ortega H, Yancey S, Cozens S. Pharmacokinetics and absolute bioavailability of mepolizumab following administration at subcutaneous and intramuscular sites. Clin Pharmacol Drug Dev. 2014; 3(1):57-62.